EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening

Nikita Mehta, Marco Ho Ting Keung, Eunice Pineda, Elliott Lynn, Dagnachew Fetene, Alvin Lee, Nicolas Hougardy, Amelie Heinrichs, Hiu Tat Mark Chan, Marc Arbyn iD, Marion Saville iD, David Hawkes iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.01493-24 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Nikita Mehta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Australian Centre for the Prevention of Cervical Cancer, Carlton, Victoria, Australia. Hauptthemen laut MEDLINE: Papillomavirus Infections, Sensitivity and Specificity, Uterine Cervical Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Holding | Roche Diagnostics (Roche Diagnostics Corporation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assessed the relative clinical sensitivity and specificity, as well as reproducibility, for high-risk HPV types of the Roche cobas HPV test when processed using the Roche cobas 5800 system. The results from this study demonstrate that the cobas HPV test using the cobas 5800 system fulfils the Meijer criteria for use in population-based cervical screening. This clinical validation study also examines the clinical sensitivity and specificity based on partial genotyping, with separate detection of HPV16 and HPV18, compared with the Roche cobas 4800 HPV test, a second-generation standard comparator assay. The cobas HPV test has a relative clinical sensitivity of 1.000, when compared with the cobas 4800 HPV test to detect histologically confirmed CIN2+ lesions in woman aged 30 years or older, with a relative clinical specificity of 0.995. The general intra- and inter-laboratory agreement for the cobas HPV test on the cobas 5800 system for finding a HPV positive result were 99.1% and 99.6%, respectively. IMPORTANCE This study demonstrates, for the first time, the clinical performance of the Roche cobas HPV test when processed using the new cobas 5800 system [cobas (5800)]. This study shows that the cobas (5800) demonstrates relative clinical sensitivity and specificity, when compared with a standard comparator HPV test, which meets the international HPV test validation requirements. Intra- and inter-laboratory reproducibility also fulfills these criteria. The current study demonstrates that the cobas (5800) can be used for primary HPV-based cervical screening on cervical specimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsSensitivity and SpecificityUterine Cervical NeoplasmsEarly Detection of CancerHumansFemaleAdultReproducibility of ResultsMiddle AgedPapillomaviridaeMass ScreeningAgedUterine Cervical DysplasiaHuman papillomavirus 18Human papillomavirus 16Cervix UteriGenotype

Stichwörter der Autor:innen

HPVcervical intraepithelial neoplasiacervical screeningclinical validationdiagnostic

Autor:innen und Institutionen

  • Australian Centre for the Prevention of Cervical Cancer, Carlton, Victoria, Australia.
  • Molecular Laboratory, Vivalia Hospital, Arlon, Belgium.
  • Department of Physiology, Anatomy and Microbiology, LaTrobe University, Bundoora, Victoria, Australia.
  • Belgian Cancer Centre/Unit of Cancer Epidemiology, Sciensano, Brussels, Belgium.
  • Department of Obstetrics and Gynaecology, University of Malaya, Kuala Lumpur, Malaysia.
  • Department of Biochemistry and Pharmacology, The University of Melbourne, Victoria, Australia.

ORCID-Profile: Marc Arbyn, Marion Saville, David Hawkes

Förderung

  • Roche Holding | Roche Diagnostics (Roche Diagnostics Corporation)

Zitieren

APA

Mehta, N., Keung, M. H. T., Pineda, E., Lynn, E., Fetene, D., Lee, A., Hougardy, N., Heinrichs, A., Chan, H. T. M., Arbyn, M., Saville, M., & Hawkes, D. (2024). Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01493-24

Vancouver

Mehta N, Keung MHT, Pineda E, Lynn E, Fetene D, Lee A, et al. Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening. Microbiology Spectrum. 2024. doi:10.1128/spectrum.01493-24

BibTeX
@article{Mehta2024,
  author = {Mehta, Nikita and Keung, Marco Ho Ting and Pineda, Eunice and Lynn, Elliott and Fetene, Dagnachew and Lee, Alvin and Hougardy, Nicolas and Heinrichs, Amelie and Chan, Hiu Tat Mark and Arbyn, Marc and Saville, Marion and Hawkes, David},
  title = {Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.01493-24}
}
Kostenlos starten →